Cited by 22Heart Failure Treatment and ManagementDiabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Sodium-glucose cotransporter-2 inhibitors in heart failure: racial differences and a potential for reducing disparities

Open access
Morris, Alanna A., Testani, Jeffrey M., Butler, Javed·2021·Circulation

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.120.052821

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Black individuals have higher prevalence of type 2 diabetes, heart failure, chronic kidney disease, and premature coronary artery disease, along with worse cardiovascular outcomes.

    “This gap is especially concerning given the higher prevalence of T2DM, heart failure, chronic kidney disease, and premature CAD among Black individuals, along with worse cardiovascular outcomes [14,15].”

    From Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease (2026) · cites this paper as [14]

    The main text (page unavailable) says Black patients have a high prevalence of heart failure, diabetes, and chronic kidney disease, and reports higher rates of death and hospitalization from heart failure. It does not specify type 2 diabetes or address premature coronary artery disease; it also does not explicitly compare diabetes or kidney-disease prevalence with other groups. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 5 · Cited by 22

Authors
Morris, A. A., Testani, J. M., & Butler, J.
Affiliations
  • Emory University (US)
  • Yale University (US)
  • University of Mississippi (US)
Venue
Circulation
Published
2021-06-15
Volume
143
Issue
24
Pages
2329-2331
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W3169938601
Cited by
22
References
5
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 1
FWCI
2.51
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (UL1TR001863)
  • National Heart, Lung, and Blood Institute (R03HL146874)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
SGLT2 inhibitors, heart failure, racial disparities, ethnic differences, health disparities
MeSH terms
Race Factors, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Hospitalization, Humans, Black People, Healthcare Disparities

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review